Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 82 Neoplasms 47 Carcinoma, Non-Small-Cell Lung 28 Colorectal Neoplasms 20 Neoplasm Metastasis 15 Multiple Myeloma 14 Thyroid Neoplasms 13 Glioma 12 Pancreatic Neoplasms 11 Hematologic Neoplasms 10 Thyroid Carcinoma, Anaplastic 9 Brain Neoplasms 8 Lung Neoplasms 7 Triple Negative Breast Neoplasms 5 Skin Neoplasms 5 Rectal Neoplasms 5 Neurofibromatosis 1 5 Lymphoma 5 Leukemia, Myeloid, Acute 5 Colonic Neoplasms 5 Breast Neoplasms 5 Astrocytoma 5 Thyroid Cancer, Papillary 4 Recurrence 4 Prostatic Neoplasms 4 Neurofibroma, Plexiform 4 Glioblastoma 4 Cholangiocarcinoma 4 Biliary Tract Neoplasms 4 Uveal Melanoma 3

Interventions

Nivolumab 20 Ipilimumab 10 Surveys and Questionnaires 7 Paclitaxel 7 linrodostat 6 Standard of Care 6 Sirolimus 5 Gemcitabine 5 Bevacizumab 5 temsirolimus 4 relatlimab 4 Pemetrexed 4 Interviews as Topic 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Vorinostat 3 Erlotinib Hydrochloride 3 Dasatinib 3 Cetuximab 3 regorafenib 2 olaparib 2 apatinib 2 anlotinib 2 abemaciclib 2 Trastuzumab 2 Sunitinib 2 Sorafenib 2 Olanzapine 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancer × trametinib × Clear all

NCT01287546 2017-02-15

A Study of LY2875358 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡